Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2008-02-21
2011-12-06
Graser, Jennifer (Department: 1645)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S142100, C424S164100, C424S246100, C530S350000, C530S388100, C530S387100, C530S388150
Reexamination Certificate
active
08071100
ABSTRACT:
The present invention relates to monoclonal antibodies that bind or neutralize anthrax lethal factor (LF), edema factor (EF), and/or protective antigen (PA). The invention provides such antibodies, fragments of such antibodies retaining anthrax toxin-binding ability, fully human or humanized antibodies retaining anthrax toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.
REFERENCES:
patent: WO 2005/120567 (2005-12-01), None
Rudikoff et al (Proc Natl Acad Sci USA 1982 vol. 79 p. 1979).
MacCallum et al. J. Mol. Biol. (1996) 262,732-745.
Pascalis et al. The Journal of Immunology (2002) 169, 3076-3084.
Casset et al. (2003) BBRC 307, 198-205.
Vajdos et al. J. of Molecular Biology (2002) 320, 415-428.
Holm et al. Molecular Immunology. (2007) 44, 1075-1084.
Chen et al. J. Mol. Bio. (1999) 293, 865-881.
Wu et al. J. Mol. Biol. (1999) 294, 151-162.
Arora, N. et al., “Fusions of anthrax toxin lethal factor with shiga toxin and diphtheria toxin enzymatic domains are toxic to mammalian cells,” Infect Immun., Nov. 1994, ;62(11):4955-61.
Brossier, F. et al, “Infect Immun. Nov. 2004;72(11):6313-7,” Infect Immun, Nov. 2004 72(11):6313-7.
Chen, Z. et al, “Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus,” Proc Natl Acad Sci USA, Feb. 2006, 103(6):1882-7; Epub Jan. 25, 2006.
Chen, Z. et al., “Efficient neutralization of anthrax toxin by chimpanzee monoclonal antibodies against protective antigen,” J Infect Dis., Mar. 2006, 193(5):625-33, Epub Feb. 2, 2006.
Galloway, D. et al., “Genetic immunization against anthrax,” Vaccine, Apr. 2004, 22(13-14):1604-8.
Lim, Nam-Kyu, et al., “An Anthrax Lethal Factor-Neutralizing Monoclonal Antibody Protects Rats before and after Challenge with Anthrax Toxin,” Infection and Immunity, vol. 73, No. 10, Oct. 1, 2005, pp. 6547-6551.
Little, S.F., et al., “Production and Characterization of Monoclonal Antibodies against the Lethal Factor Component ofBacillus anthracislethal toxin”, Infection and Immunity, vol. 58, No. 6, Jun. 1990, pp. 1606-1613.
Little, S. F. et al., “Production and characterization of monoclonal antibodies to the protective antigen component ofBacillus anthracistoxin,” Infect Immun, Jul. 1988, 56(7):1807-13.
Little, F Stephen, “Structure-Function Analysis ofBacillus anthracisedema factor by using moriclonal antibodies,” Biochemical and Biophysical Research Communications, vol. 199, No. 2, Mar. 15, 1994, pp. 676-682.
Maynard, J. A. et al., “Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity,” Nat Biotechnol, Jun. 2002, 20(6):597-601.
Milne, J. C. et al., “Protective antigen-binding domain of anthrax lethal factor mediates translocation of a heterologous protein fused to its amino- or carboxy-terminus,” Mol Microbiol, Feb. 1995, 15(4):661-6.
Peterson, J. W. et al., “Human monoclonal antibody AVP-21D9 to protective antigen reduces dissemination of theBacillus anthracisAmes strain from the lungs in a rabbit model,” Infect Immun, Jul. 2007, 75(7):3414-24; Epub Apr. 23, 2007.
Pezard, C. et al., “Protective immunity induced byBacillus anthracistoxin-deficient strains,” Infect Immun, Apr. 1995, 63(4):1369-72.
Price, B. M. et al., “Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein,” Infect Immun, Jul. 2001 69(7):4509-15.
Sawada-Hirai, R. et al., “Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed,” J Immune Based Ther Vaccines, May 2004, 2(1):5.
Varughese, M. et al., “Internalization of aBacillus anthracisprotective antigen-c-Myc fusion protein mediated by cell surface anti-c-Myc antibodies,” Mol Med, Feb. 1998, 4(2):87-95.
Vitale, L. et al., “Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity,” Infect Immun, Oct. 2006, 74(10):5840-7.
Wild, M. A. et al., “Human antibodies from immunized donors are protective against anthrax toxin in vivo,” Nat Biotechnol, Nov. 2003, 21(11):1305-6; Epub Oct. 12, 2003.
Zhao, Ping et al., “Neutralizing monoclonal antibody against Anthrax lethal factor inhibits intoxication in a mouse model,” Human Antibodies, vol. 12, No. 4, Jan. 1, 2003, pp. 129-135.
Chen Zhaochun
Emerson Suzanne U.
Leppla Stephen H.
Moayeri Mahtab
Purcell Robert H.
Graser Jennifer
Sheridan & Ross P.C.
The Unites States of America as represented by the Secretary of
LandOfFree
Monoclonal antibodies that neutralize anthrax toxins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibodies that neutralize anthrax toxins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibodies that neutralize anthrax toxins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4298261